October 2005
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1354
Academic Journal
Reports that the U.S. Food and Drug Administration (FDA) has issued a warning letter intended for Boehringer Ingelheim Pharmaceuticals Inc. due to the violations the pharmaceutical company has committed with regards to the provision of the drug advertising and promotion regulations. Conclusion from FDA that the advertising campaign was misleading from the facts regarding Atrovent (ipratropium bromide) and Combivent ( Ipratropium bromide and albuterol sulfate) Inhalation Aerosols; Failure of the campaign to describe the indications and limitations for the utilization of the chemicals; Important facts about the two chemical agents issued by FDA.


Related Articles

  • Pharma: Other News To Note.  // BioWorld Today;9/18/2013, Vol. 24 Issue 179, p5 

    The article offers information the breakthrough therapy designation granted to the volasertib drug of Boehringer Ingelheim Pharmaceuticals Inc. and the drug approval of Treanda (bendamustine HCI) injection from Teva Pharmaceutical Industries Ltd. by the U.S. Food and Drug Administration (FDA).

  • Costs and Compliance Dominate Agenda for 2011. Wechsler, Jill // Pharmaceutical Technology;Jan2011, Vol. 35 Issue 1, p26 

    The article offers information on the programs of the U.S. Food and Drug Administration (FDA) for pharmaceutical manufacturers. It states that the Prescription Drug User Fee Act (PDUFA) needs to be reauthorized by October 1, 2012 for FDA to proceed collecting around 700 million dollars payment....

  • FDA revises application process.  // Ophthalmology Times;8/15/2008, Vol. 33 Issue 16, p7 

    The article reports on the U.S. Food & Drug Administration's (FDA) announcement related to reviewing its communication procedure with drug companies. The changes are applicable under conditions when a marketing application can't be approved as submitted. Under new regulations governing the drug...

  • Institute of Medicine report calls for extensive overhaul of drug safety procedures at FDA, CDER. Nagy, Benjamin // Formulary;Nov2006, Vol. 41 Issue 11, p607 

    The article reports on the measures taken to improve the drug safety procedures at the Food & Drug Administration (FDA) and the Center for Drug Evaluation and Research (CDER). It is stated that after FDA's removal of rofecoxib, several legislators and scientific communities asked for medication...

  • FYI: CMC Pilot Program drug approved. Wechsler, Jill // Pharmaceutical Technology;Oct2006, Vol. 30 Issue 10, p46 

    The article reports on the approval of a novel drug application by the Office of New Drug Quality Assessment in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research in the U.S. This enabled the agency and drug manufacturers to include quality-by-design principles and...

  • FDA's Hiring Challenge. Winkle, Helen // BioPharm International;Oct2007, Vol. 20 Issue 10, p145 

    The article discusses the challenges faced by Food and Drug Administration (FDA) in hiring properly educated pharmaceutical scientists. It is said that hiring and retaining skilled pharmaceutical scientists has been a challenge for the Center for Drug Evaluation and Research. According to the...

  • FDA Update.  // Renal & Urology News;Nov2009, Vol. 8 Issue 11, p50 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The U.S. Food and Drugs Administration (FDA) has approved the Votrient for the treatment of advance renal cell carcinoma (RCC). The FDA has granted a marketing clearance for Colcrys, a new colchincine formulation...

  • An Overview of the CDER Drug Recall Root Cause Research Project. Torbeck, Lynn; Friedman, Richard; Smedley, Michael // Pharmaceutical Technology;Aug2009, Vol. 33 Issue 8, p42 

    This article provides an overview of the drug Recall Root Cause Research (RRCR) project, an initiative of the US Food and Drug Administration's Center for Drug Evaluation and Research. The project's objective is to positively influence the understanding and evaluation of drug-product quality...

  • Stay Afloat with Lessons Learned. Drakulich, Angie // Pharmaceutical Technology;Nov2009, Vol. 33 Issue 11, p14 

    The article discusses the pronouncement of U.S. Food and Drug Administration's (FDA) associate director Edwin Rivera-Martinez on the strategies for the pharmaceutical industry to stay afloat. The director at the Center for Drug Evaluation and Research Office has urged the pharmaceutical industry...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics